GRTS up 35%. Some more information:

Gritstone Oncology Inc (GRTS) is trading 35% higher at $5.49 today. The stock is outperforming peers on a rather dull day for the healthcare sector as a whole. The share price is surging up on the publication of data from its clinical trials for it's flagship product GRANITE, a vaccine for solid tumors.

Gritstone Oncology Inc has been trading between a 52-week high of $14.42 and a 52-week low of $1.71. The stock has a market cap of $400 Million.

Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies.